E-PSMA: the EANM Standardized Reporting Guidelines V1.0 for PSMA-PET

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2021 Feb 19

PMID 33604691

Citations 122

Authors

Francesco Ceci

Daniela E Oprea-Lager

Louise Emmett

Judit A Adam

Jamshed Bomanji

Johannes Czernin

Matthias Eiber

Uwe Haberkorn

Michael S Hofman

Thomas A Hope

Rakesh Kumar

Steven P Rowe

Sarah M Schwarzenboeck

Stefano Fanti

Ken Herrmann

Affiliations

Soon will be listed here.

Abstract

Rationale: The development of consensus guidelines for interpretation of Prostate-Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide more consistent reports in clinical practice. The standardization of PSMA-PET interpretation may also contribute to increasing the data reproducibility within clinical trials. Finally, guidelines in PSMA-PET interpretation are needed to communicate the exact location of findings to referring physicians, to support clinician therapeutic management decisions.

Methods: A panel of worldwide experts in PSMA-PET was established. Panelists were selected based on their expertise and publication record in the diagnosis or treatment of PCa, in their involvement in clinical guidelines and according to their expertise in the clinical application of radiolabeled PSMA inhibitors. Panelists were actively involved in all stages of a modified, nonanonymous, Delphi consensus process.

Results: According to the findings obtained by modified Delphi consensus process, panelist recommendations were implemented in a structured report for PSMA-PET.

Conclusions: The E-PSMA standardized reporting guidelines, a document supported by the European Association of Nuclear Medicine (EANM), provide consensus statements among a panel of experts in PSMA-PET imaging, to develop a structured report for PSMA-PET in prostate cancer and to harmonize diagnostic interpretation criteria.

Citing Articles

The prognostic role of staging [18F]PSMA-1007 PET/CT volumetric and dissemination features in prostate cancer.

Albano D, Temponi A, Bertagna F, Suardi N, Talin A, Bonu M Ann Nucl Med. 2025; .

PMID: 39961974 DOI: 10.1007/s12149-025-02026-7.

Association of [Ga]Ga-PSMA-11 PET/CT Metrics with PSA Persistence Following Radical Prostatectomy in Patients with Intermediate- and High-Risk Prostate Cancer.

Rosales J, Betech-Antar V, Minguez F, Guillen E, Prieto E, Quincoces G Diagnostics (Basel). 2025; 15(3).

PMID: 39941231 PMC: 11817176. DOI: 10.3390/diagnostics15030301.

Exploring the Correlation Between Multiparameters Detected in Primary Prostate Cancer using F‑18 PSMA‑1007 PET/MRI and their Potential for Predicting Metastasis.

Cheewadhanaraks S, Sereeborwornthanasak K, Siripongsatian D, Jantarato A, Promteangtrong C, Kunawudhi A Nucl Med Mol Imaging. 2025; 59(1):79-90.

PMID: 39881967 PMC: 11772630. DOI: 10.1007/s13139-024-00884-z.

[F]PSMA-1007 PET/CT-based radiomics may help enhance the interpretation of bone focal uptakes in hormone-sensitive prostate cancer patients.

Bauckneht M, Pasini G, Di Raimondo T, Russo G, Raffa S, Donegani M Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39873702 DOI: 10.1007/s00259-025-07085-6.

Current insights on PSMA PET/CT in intermediate-risk prostate cancer: a literature review.

Guglielmo P, Buffi N, Porreca A, Setti L, Arico D, Muraglia L Ann Nucl Med. 2025; 39(3):247-254.

PMID: 39812950 DOI: 10.1007/s12149-025-02015-w.

References

OKeefe D, Bacich D, Huang S, Heston W . A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies. J Nucl Med. 2018; 59(7):1007-1013. PMC: 6910646. DOI: 10.2967/jnumed.117.203877. View

Gordon I, Tretiakova M, Noffsinger A, Hart J, Reuter V, Al-Ahmadie H . Prostate-specific membrane antigen expression in regeneration and repair. Mod Pathol. 2008; 21(12):1421-7. DOI: 10.1038/modpathol.2008.143. View

Kaittanis C, Andreou C, Hieronymus H, Mao N, Foss C, Eiber M . Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med. 2017; 215(1):159-175. PMC: 5748857. DOI: 10.1084/jem.20171052. View

Aggarwal R, Wei X, Kim W, Small E, Ryan C, Carroll P . Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. Eur Urol Oncol. 2019; 1(1):78-82. DOI: 10.1016/j.euo.2018.03.010. View

Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R . Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade. J Nucl Med. 2018; 60(7):950-954. DOI: 10.2967/jnumed.118.223099. View

Fendler W, Weber M, Iravani A, Hofman M, Calais J, Czernin J . Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019; 25(24):7448-7454. DOI: 10.1158/1078-0432.CCR-19-1050. View

Eder M, Schafer M, Bauder-Wust U, Hull W, Wangler C, Mier W . 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012; 23(4):688-97. DOI: 10.1021/bc200279b. View

Gillessen S, Omlin A, Attard G, de Bono J, Efstathiou E, Fizazi K . Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2016; 30(12):e3. DOI: 10.1093/annonc/mdw180. View

Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I . Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and.... Eur Urol. 2019; 77(4):403-417. DOI: 10.1016/j.eururo.2019.01.049. View

10.

Calais J, Ceci F, Eiber M, Hope T, Hofman M, Rischpler C . F-fluciclovine PET-CT and Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019; 20(9):1286-1294. PMC: 7469487. DOI: 10.1016/S1470-2045(19)30415-2. View

11.

Morigi J, Stricker P, van Leeuwen P, Tang R, Ho B, Nguyen Q . Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. J Nucl Med. 2015; 56(8):1185-90. DOI: 10.2967/jnumed.115.160382. View

12.

Fendler W, Calais J, Eiber M, Flavell R, Mishoe A, Feng F . Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019; 5(6):856-863. PMC: 6567829. DOI: 10.1001/jamaoncol.2019.0096. View

13.

Kratochwil C, Fendler W, Eiber M, Baum R, Bozkurt M, Czernin J . EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019; 46(12):2536-2544. DOI: 10.1007/s00259-019-04485-3. View

14.

Fanti S, Minozzi S, Morigi J, Giesel F, Ceci F, Uprimny C . Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. Eur J Nucl Med Mol Imaging. 2017; 44(10):1622-1635. DOI: 10.1007/s00259-017-3725-1. View

15.

Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel F, Hartenbach M . Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J Nucl Med. 2017; 59(3):469-478. DOI: 10.2967/jnumed.117.198119. View

16.

Fendler W, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S . Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017; 44(6):1014-1024. DOI: 10.1007/s00259-017-3670-z. View

17.

Chen Y, Pullambhatla M, Foss C, Byun Y, Nimmagadda S, Senthamizhchelvan S . 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011; 17(24):7645-53. PMC: 3243762. DOI: 10.1158/1078-0432.CCR-11-1357. View

18.

Mease R, Dusich C, Foss C, Ravert H, Dannals R, Seidel J . N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008; 14(10):3036-43. PMC: 3078104. DOI: 10.1158/1078-0432.CCR-07-1517. View

19.

Sanchez-Crespo A . Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot. 2012; 76:55-62. DOI: 10.1016/j.apradiso.2012.06.034. View

22.

Zlatopolskiy B, Endepols H, Krapf P, Guliyev M, Urusova E, Richarz R . Discovery of F-JK-PSMA-7, a PET Probe for the Detection of Small PSMA-Positive Lesions. J Nucl Med. 2018; 60(6):817-823. PMC: 6581226. DOI: 10.2967/jnumed.118.218495. View